Resverlogix’s 2017 Outlook

Read story

ESC Congress 2017

Read story

ERA-EDTA Congress 2017

Read story

ESC Congress 2016

Read story

EASD 2016

Read story

European Biopharmaceutical Review

Read story

New York Academy of Science Symposium

Read story

The Complement System: Part 1

Read story

The Complement System: Part 2

Read story

The Complement System: Part 3

Read story

Diabetes Mellitus

Read story

Chronic Kidney Disease

Read story

The New Frontier of Epigenetics

Read story

Readers, Writers & Erasers in Epigenetics

Read story

Clinical Trials Series: Part 1

Read story

Clinical Trials Series: Part 2

Read story

Clinical Trials Series: Part 3

Read story

Pharmacoeconomics

Read story

Sanofi Biogenius Competition CTV News feature

Read story

World Diabetes Day

Read story

ERA-EDTA Congress 2017

On June 5, 2017, Resverlogix hosted a symposium titled: "Managing CKD, Diabetes & CVD: Is epigenetics a new way forward?" at the ERA-EDTA Congress in Madrid, Spain.

Introduction

Vincent M Brandenburg, MD – Aachen, Germany

The high risk diabetes patient: What is the need for novel approaches to reduce cardiovascular and renal risk?

Luis M Ruilope, MD – Hospital 12 de Octubre, Madrid, Spain

Epigenetics as a novel strategy in cardiovascular and renal risk reduction: A closer look at BET as a pathway for inhibition

Marta Ruiz-Ortega – Foundación Jiménez Diaz, Madrid, Spain

BET inhibition in renal and cardiovascular disease: What is the clinical roadmap?

Kamyar Kalantar-Zadeh, MD – UC Irvine School of Medicine, Irvine, USA

Discussion & Summary

Carmine Zoccali, MD – Reggio Cal, Italy

Video Presentations & Symposium Highlights can be accessed HERE